NEMLUVIO Trademark

Trademark Overview


On Friday, December 1, 2023, a trademark application was filed for NEMLUVIO with the United States Patent and Trademark Office. The USPTO has given the NEMLUVIO trademark a serial number of 79387842. The federal status of this trademark filing is REGISTERED as of Tuesday, October 15, 2024. This trademark is owned by Galderma Holding SA. The NEMLUVIO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of dermatology conditions, namely, dermatitis, psoriasis, acne, eczema, skin cancer, hives, lupus, rosacea, vitiligo, hives, dermatomyositis, actinic keratosis, cellulitis. Cold sore, wart, autoimmune , and candidiasis; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use with skin care; pharmaceutical preparations for the treatment of immune related inflammatory diseases; pharmaceutical preparations for the treatment of atopic dermatitis and prurigo nodularis
nemluvio

General Information


Serial Number79387842
Word MarkNEMLUVIO
Filing DateFriday, December 1, 2023
Status700 - REGISTERED
Status DateTuesday, October 15, 2024
Registration Number7532663
Registration DateTuesday, October 15, 2024
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, July 30, 2024

Trademark Statements


Description of MarkThe mark consists of of the stylized purple wording "NEMLUVIO" to the right of a tapering petal design. The petal design consists of four petals: one orange, one purple, one light purple, and one beige in order from bottom left to top right.
Description of the Colors ClaimedNemluvio word is purple, the petals are the other colors.
Goods and ServicesPharmaceutical preparations for the treatment and prevention of dermatology conditions, namely, dermatitis, psoriasis, acne, eczema, skin cancer, hives, lupus, rosacea, vitiligo, hives, dermatomyositis, actinic keratosis, cellulitis. Cold sore, wart, autoimmune , and candidiasis; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use with skin care; pharmaceutical preparations for the treatment of immune related inflammatory diseases; pharmaceutical preparations for the treatment of atopic dermatitis and prurigo nodularis
Indication of Colors claimedThe color(s) purple, light purple, beige and orange is/are claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, January 26, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGalderma Holding SA
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressCH

Party NameGalderma Holding SA
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCH

Party NameGalderma Holding SA
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCH

Trademark Events


Event DateEvent Description
Tuesday, January 30, 2024APPLICATION FILING RECEIPT MAILED
Thursday, January 25, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, January 26, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 22, 2024ASSIGNED TO EXAMINER
Thursday, May 9, 2024REFUSAL PROCESSED BY IB
Thursday, March 28, 2024NON-FINAL ACTION WRITTEN
Friday, March 29, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, April 16, 2024REFUSAL PROCESSED BY MPU
Wednesday, April 17, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sunday, April 21, 2024NEW REPRESENTATIVE AT IB RECEIVED
Wednesday, June 26, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 26, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 26, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 26, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, July 10, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 30, 2024PUBLISHED FOR OPPOSITION
Tuesday, July 30, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 15, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, October 15, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED